Receive The Newest Study Notifications

CD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two Patients Proof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T Cells Against Hotspot Mutations Antigen Spreading Confirmed July 15, 2019 08:00 AM Eastern...

FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, announced today that the first participant has been enrolled in the Company’s...

Mark Terry writes: The majority of clinical trials are conducted at major research institutions or clinics, often based in urban areas. This can create problems of accessibility for many potential patients who live more than two hours from a trial site or who have...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2 study evaluating IDE196 in Patients with Solid Tumors Harboring GNAQ/11...

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently announced that it...

The first patient has been dosed in an ongoing phase 1/2a clinical trial with a new thaw-and-inject formulation of OpRegen, delivered with the Orbit subretinal delivery system, BioTime announced in a press release. The open-label, dose escalation trial will evaluate...

Pulmatrix, Inc. has reportedly activated three sites in the United States for the phase-2 clinical trial of Pulmazole (PUR1900). It is an inhaled formulation consisting of itraconazole for treating allergic bronchopulmonary aspergillosis (ABPA) in patients suffering...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled,...

Nordic Nanovector ASA (NANO.OL) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell...

 Medidata (NASDAQ: MDSO) announced today that Catalyst Clinical Research chose the Medidata Rave Clinical Cloud™ for its one-platform approach to clinical trials. By adopting Medidata Rave CTMS combined with Rave EDC and Rave eTMF, Catalyst immediately offers a...

The University of Colorado Cancer Center is leading the way in the development of a new endometrial cancer clinical trial that may lead to practice-changing therapies in the future. Bradley Corr smilingBradley Corr, MD "We are excited to be one of the first cancer...

TARIS Bio™ today announced the dosing of the first patient in a Phase 1b clinical trial evaluating the investigational product TAR-200 in combination with Opdivo® (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor from Bristol-Myers Squibb. The...

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled,...

Positive early outcomes in complex in-stent restenosis cases with few therapeutic options Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery...

The Alberta Diabetes Institute (ADI) will be at the centre of a new clinical trial for an anti-obesity drug targeting people with rare genetic conditions that contribute to their obesity. Led by Andrea Haqq, clinical scientist at the ADI and associate professor in the...

SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in...

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it is developing a new proprietary modified-release oral tablet form...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple...

Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has initiated the EQUIP Phase 1b clinical...

Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has...